NCT01763190View on ClinicalTrials.gov

Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Renal Impairment
Interventions
DRUG

SAR302503

"Pharmaceutical form:capsule~Route of administration: oral"

Trial Locations (3)

32809

Investigational Site Number 840002, Orlando

37920

Investigational Site Number 840001, Knoxville

55144

Investigational Site Number 840003, Saint Paul

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY